Search
Cardiff Oncology Inc
CRDFAdd to Watchlist
0.990USD
0.0000.00%
Close 08-14 16:00（ET）Quotes delayed by 15 min
67.82MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Cardiff Oncology Inc is 7.25, ranking 298 out of 387 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 19.00 and a low of 3.50.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
7.500
Target Price
+678.82%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cardiff Oncology Inc
CRDF
8
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cardiff Oncology Inc's expected revenue for the next quarter?
Cardiff Oncology Inc's expected revenue is 75.00K.
What is Cardiff Oncology Inc's price target?
Analysts forecast that Cardiff Oncology Inc's price target is USD 10.00, with the highest forecast at USD 19.00 and the lowest forecast at USD 3.50.
How have Cardiff Oncology IncCRDF's recent earnings per share performed?
The market expectation was USD -0.14, while Cardiff Oncology IncCRDF's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Cardiff Oncology Inc?
Based on the ratings of Cardiff Oncology Inc's stock from 8 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.